Trialect

Active

Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) uses a R61/R33 Phased Innovation Award activity code to support clinical research applications that are exploratory and developmental in nature and focus on understanding the neurobiological mechanisms underlying substance use disorders (SUD), including fundamental circuitry and behavior relevant to substance use. Note: For basic science experimental studies involving humans, referred to in NOT-OD-18-212 as “prospective basic science studies involving human participants” please use the companion NOFO - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH)) PAR-23-282

For projects not requiring a phased research approach, applicants are encouraged to apply under a different funding activity code (e.g., PA-20-183 “Research Project Grant (Parent R01 Clinical Trial Required)”).

Companion FOA: PAR-23-158 , R61 / R33 Phase 1 Exploratory/Developmental Grant/ Exploratory/Developmental Grants Phase II

Deadlines:

Letter of Intent Due Date(s): 30 days prior to the application due date
Application Due Date(s): June 21, 2023; Oct 9, 2023; March 13, 2024; June 20, 2024; Oct 9, 2024; March 13, 2025; June 20, 2025; Oct 9, 2025; March 13, 2026
AIDS Application Due Date(s): Jan. 7, May 7, Sep. 7

PAR-23-157 Expiration Date May 08, 2026

Specialties

Medical

Medical - Clinical Science

Eligibility Requirements

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

View Funding Opportunity

Grant

Final Deadline:

Oct 09, 2024

LOI Deadline: 30 days prior to the application due date Application Due Date(s): June 21, 2023; Oct 9, 2023; March 13, 2024; June 20, 2024; Oct 9, 2024; March 13, 2025; June 20, 2025; Oct 9, 2025; March 13, 2026